Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | TPH1 | P17752 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31089960 | 0.86 | SIGMAR1 (0.40) | SIGMAR1PRMT5SCN9ATPH1 | |
| SCHEMBL99142 | 0.86 | SIGMAR1 (0.40) | SIGMAR1PRMT5SCN9ATPH1 | |
| SCHEMBL21201777 | 0.85 | SIGMAR1 (0.39) | SIGMAR1PRMT5SCN9ATPH1 | |
| SCHEMBL17539275 | 0.85 | SIGMAR1 (0.39) | SIGMAR1PRMT5SCN9ATPH1 | |
| SCHEMBL17387449 | 0.84 | SIGMAR1 (0.39) | SIGMAR1PRMT5SCN9ATPH1 | |
| SCHEMBL19790077 | 0.83 | SIGMAR1 (0.42) | SIGMAR1PRMT5SCN9ATPH1 | |
| SCHEMBL18638756 | 0.83 | AURKA (0.40) | — | |
| SCHEMBL19059356 | 0.82 | SIGMAR1 (0.40) | SIGMAR1PRMT5SCN9ATPH1PIK3CG | |
| SCHEMBL19304149 | 0.81 | GRK2 (0.32) | — | |
| SCHEMBL13286173 | 0.80 | SIGMAR1 (0.46) | SIGMAR1PRMT5SCN9ATPH1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172863-A1 | MODIFIED-RELEASE DOSAGE FORMS OF RUXOLITINIB | ARBOR PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | INCYTE HOLDINGS CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3771716-A1 | LOW HYGROSCOPIC AMORPHOUS FORM OF BARICITINIB | Zaklady Farmaceutyczne "Polpharma" S.A. (PL) | 2021-02-03 | — | — | EP | disclosed |
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | JAK1, JAK3, JAK2 | SIGMAR1 2072/4885PRMT5 433/4885SCN9A 4060/4885 |
| US-20230172863-A1 | MODIFIED-RELEASE DOSAGE FORMS OF RUXOLITINIB | JAK1, JAK3, JAK2 | SIGMAR1 2728/4885PRMT5 248/4885SCN9A 4195/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | SIGMAR1 3460/4885PRMT5 656/4885SCN9A 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.